Recent Comments

Comment RSS

Azithromycin News and Research RSS Feed - Azithromycin News and Research

Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

13. November 2009 11:29
Tianyin Pharmaceutical Co., Inc., a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its first quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags:

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

5. November 2009 07:51
Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share. [More]

Patient enrollment in three late-stage clinical trials completed

5. November 2009 01:01
Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials. [More]

Posted in: Drug Trial News

Tags: , , , , , , ,

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

15. October 2009 07:43
Inspire Pharmaceuticals, Inc. announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , ,

Tianyin Pharmaceutical announces fiscal 2009 financial results

24. September 2009 09:27
Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009. [More]

Posted in: Business / Finance

Tags:

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

15. September 2009 00:52
InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). [More]

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

10. September 2009 05:56
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). [More]

Antibiotic used to treat trachoma reduces child mortality in Ethiopia, study finds

2. September 2009 23:56
The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports. [More]

Posted in: Child Health News

Tags: , , , , , ,

Eye disease medication lowers death rate among Ethiopian children

2. September 2009 00:38
Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA. [More]

Hospira receives FDA approval for Azithromycin for injection

30. June 2009 03:09
Hospira, Inc has announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System. [More]

Posted in: Pharmaceutical News

Tags: , , ,

Sagent Pharmaceuticals receives FDA approval of Azithromycin for injection

26. March 2009 17:40
Sagent Pharmaceuticals, Inc. has announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use. [More]

Discovery of better treatment for bacterial pneumonia

9. January 2009 05:04
Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Chlamydia treatment in UK pharmacies will deliver convenient care for patients

5. August 2008 23:38
Today's decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB). [More]

Posted in: Pharmaceutical News

Tags: ,

Chlamydia antibiotic available over-the-counter in the UK

5. August 2008 23:17
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor. [More]

New understanding of how some bacteria survive antibiotic treatment

30. April 2008 18:50
Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs. [More]

Posted in: Medical Research News

Tags: , , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.